復星醫藥(600196.SH):重組人胰島素產業化(原料+製劑)等3個項目結項
格隆匯5月6日丨復星醫藥(600196.SH)公佈,此次結項的募投項目名稱:重組人胰島素產業化(原料+製劑)項目、青蒿琥酯高技術產業化示範項目以及體外診斷產品生產基地項目。
節餘資金及用途:截至2021年12月31日,各專項賬户節餘資金合計人民幣669.98萬元(包括募集資金節餘人民幣331.70萬元、利息收入餘額人民幣294.48萬元以及產業公司以自有資金投入桂林南藥的增資款人民幣43.80萬元);公司擬將上述專項賬户節餘資金用於永久補充流動資金,實際永久補充流動資金金額以資金轉出相關專項賬户當日餘額為準。
根據《上海證券交易所上市公司自律監管指引第1號——規範運作》,此次以節餘募集資金(包括利息收入)永久補充流動資金可免於履行董事會及股東大會審議以及獨立非執行董事、監事會、保薦機構發表意見等相關程序。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.